Evidence map›Paper›PMID 35377407›Full record

ArticleBrain : a journal of neurology2022

Post-acute blood biomarkers and disease progression in traumatic brain injury.

Virginia F J Newcombe, Nicholas J Ashton, Jussi P Posti, Ben Glocker, Anne Manktelow, Doris A Chatfield, Stefan Winzeck, Edward Needham, Marta M Correia, Guy B Williams and 10 more

3 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 67 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 4 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06163833 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury

TypeinterventionalSponsorFondazione IRCCS San Gerardo dei TintoriRan2023 to 2026Enrolled78ConditionsTraumatic Brain Injury With Loss of ConsciousnessArmsMesenchymal stromal cell low dosage-80*10^6 cells, Mesenchymal stromal cell low dosage-160*10^6 cells, Placebo-storage solution
NCT06927063 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Long-term Recovery and Microbiota-Gut-Brain Axis Disruption After Traumatic Brain Injury

Typeobservational_patient_registrySponsorTurku University HospitalRan2025 to 2028Enrolled160ConditionsTraumatic Brain InjuryArmsblood-based protein biomarker assessments, blood-based metabolomic/lipidomic biomarker assessments, Diffusion-weighted magnetic resonance imaging (brain), Structural magnetic resonance imaging (brain), PET imaging (brain)
NCT07172841 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Randomized Controlled Study on Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus

TypeinterventionalSponsorGöteborg UniversityRan2025 to 2034Enrolled60ConditionsNormal Pressure Hydrocephalus Patients, Normal Pressure HydrocephalusArmsIntervention group "Virtual OFF", Control group (no change in shunt setting)
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 4 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026
    Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 3 countries.

Virginia F J NewcombeUniversity Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6044-9035
Nicholas J AshtonWallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Jussi P PostiNeurocenter, Department of Neurosurgery, Turku University Hospital and University of Turku, Turku, Finland.
Ben GlockerBiomedical Image Analysis Group, Department of Computing, Imperial College London, London, UK.
Anne ManktelowUniversity Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.
Doris A ChatfieldUniversity Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.
Stefan WinzeckUniversity Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.
Edward NeedhamUniversity Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7042-7462
Marta M CorreiaMRC (Medical Research Council) Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.ORCID 0000-0002-3231-7040
Guy B WilliamsWolfson Brain Imaging Centre, Department of Clinical Neurosciences, Cambridge, UK.
Joel SimrénInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0001-5081-6604
Riikka S K TakalaPerioperative Services, Intensive Care Medicine and Pain Management, Department of Anesthesiology and Intensive Care, Turku University Hospital, University of Turku, Turku, Finland.
Ari J KatilaPerioperative Services, Intensive Care Medicine and Pain Management, Department of Anesthesiology and Intensive Care, Turku University Hospital, University of Turku, Turku, Finland.
Henna Riikka MaanpääNeurocenter, Department of Neurosurgery, Turku University Hospital and University of Turku, Turku, Finland.
Jussi TallusTurku Brain Injury Center, Turku University Hospital and University of Turku, Turku, Finland.
Janek FrantzénNeurocenter, Department of Neurosurgery, Turku University Hospital and University of Turku, Turku, Finland.
Kaj BlennowInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Olli TenovuoTurku Brain Injury Center, Turku University Hospital and University of Turku, Turku, Finland.
Henrik ZetterbergInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0003-3930-4354
David K MenonUniversity Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, UK.ORCID 0000-0002-3228-9692
University of Turku · FIUniversity of Cambridge · GBSahlgrenska University Hospital · SEInstitute of Group Analysis · GBKing's College London · GBMRC Cognition and Brain Sciences Unit · GB

Funding

The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normalR01AG068398 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIANG, GLORIA CHIA-YI · 2020 to 2024
$2.8M
Biotechnology and Biological Sciences Research Council BB/H008217/1Department of HealthMedical Research Council G9439390Medical Research Council MC_UU_00005/14Medical Research Council MR/R005036/1NIA NIH HHS R01 AG068398
6 · The paper itself

Abstract

There is substantial interest in the potential for traumatic brain injury to result in progressive neurological deterioration. While blood biomarkers such as glial fibrillary acid protein (GFAP) and neurofilament light have been widely explored in characterizing acute traumatic brain injury (TBI), their use in the chronic phase is limited. Given increasing evidence that these proteins may be markers of ongoing neurodegeneration in a range of diseases, we examined their relationship to imaging changes and functional outcome in the months to years following TBI. Two-hundred and three patients were recruited in two separate cohorts; 6 months post-injury (n = 165); and >5 years post-injury (n = 38; 12 of whom also provided data ∼8 months post-TBI). Subjects underwent blood biomarker sampling (n = 199) and MRI (n = 172; including diffusion tensor imaging). Data from patient cohorts were compared to 59 healthy volunteers and 21 non-brain injury trauma controls. Mean diffusivity and fractional anisotropy were calculated in cortical grey matter, deep grey matter and whole brain white matter. Accelerated brain ageing was calculated at a whole brain level as the predicted age difference defined using T1-weighted images, and at a voxel-based level as the annualized Jacobian determinants in white matter and grey matter, referenced to a population of 652 healthy control subjects. Serum neurofilament light concentrations were elevated in the early chronic phase. While GFAP values were within the normal range at ∼8 months, many patients showed a secondary and temporally distinct elevations up to >5 years after injury. Biomarker elevation at 6 months was significantly related to metrics of microstructural injury on diffusion tensor imaging. Biomarker levels at ∼8 months predicted white matter volume loss at >5 years, and annualized brain volume loss between ∼8 months and 5 years. Patients who worsened functionally between ∼8 months and >5 years showed higher than predicted brain age and elevated neurofilament light levels. GFAP and neurofilament light levels can remain elevated months to years after TBI, and show distinct temporal profiles. These elevations correlate closely with microstructural injury in both grey and white matter on contemporaneous quantitative diffusion tensor imaging. Neurofilament light elevations at ∼8 months may predict ongoing white matter and brain volume loss over >5 years of follow-up. If confirmed, these findings suggest that blood biomarker levels at late time points could be used to identify TBI survivors who are at high risk of progressive neurological damage.

Indexed as

Brain InjuriesBrain Injuries, TraumaticWhite MatterBiomarkersDiffusion Tensor ImagingDisease ProgressionGlial Fibrillary Acidic ProteinHumansBiomarkersGlial Fibrillary Acidic Proteinglial fibrillary acid protein (GFAP)neurofilament light (NFL)neuroimagingoutcometraumatic brain injury

Identifiers

PMID35377407
PMCPMC9326940
OpenAlexW4226435506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.